Recent developments of interest in cardiovascular medicine
Taking omega-3 fatty acids was associated with less GI bleeding among left ventricular assist device patients. (Circulation: Heart Failure)
Most women would want to know if their mammogram turned up breast arterial calcification, which can predict cardiovascular disease, according to a survey in the American Journal of Roentgenology.
Smoking weed is no longer illegal in some places, but that doesn’t mean it’s safe for heart disease patients. (Cardiovascular Business)
Genetic variants associated with bleeding events on warfarin were found among people with African ancestry. (JAMA)
Appropriately trained interventional radiologists should be allowed to get in on mechanical thrombectomy, argued the Society of Interventional Radiology and its counterparts in Europe and Australasia. The groups said they’re committed to providing that training.
European regulators have asked for an in-depth analysis of the early halt to the GALILEO trial for increased all-cause mortality and thromboembolic and bleeding disorders in transcatheter aortic valve replacement patients treated with rivaroxaban (Xarelto). Physicians will get a letter warning about the issue in the meantime.
A vaccine against thrombotic events after ischemic stroke is getting closer to reality, as researchers found a shot that protected against clots without increasing bleeding risk — in mice. (Hypertension)
The expanded window of time for acute stroke intervention made the Cleveland Clinic’s top 10 for medical innovations expected to transform healthcare next year. So did a hemorrhage scanning visor to detect hemorrhagic strokes on the way to the hospital and percutaneous mitral and tricuspid valve procedures.
The FDA cleared a lower-profile version of the Valiant Captivia stent graft, dubbed Valiant Navion, for minimally invasive repair of descending thoracic aorta lesions. (FierceBiotech)
Weight-loss drug liraglutide (Saxenda) got an updated label indicating no increase in cardiovascular risk with the drug. (MPR)
Periodontal disease was associated with higher blood pressure and poorer response to antihypertensives among people with hypertension. (Hypertension)
A small addition was made to the FDA’s list of recalled valsartan products.
After the FDA said it wouldn’t give canakinumab (Ilaris) an atherosclerotic cardiovascular disease indication, the Institute for Clinical and Economic Review likewise announced it dropped its assessment of cost-effectiveness for that use.
Antiarrhythmic IV drug vernakalant (Brinavess) is being resubmitted for FDA approval for rapid conversion of recent-onset atrial fibrillation, Correvio Pharma announced.
No surprise: More vigorous exercise was associated with less accumulation of cardiovascular and diabetes risk factors in children. (Scandinavian Journal of Medicine & Science in Sports)
Credit: www.medpagetoday.com